Development of an apolipoprotein E mimetic peptide-lipid conjugate for efficient brain delivery of liposomes

Drug Deliv. 2023 Dec;30(1):2173333. doi: 10.1080/10717544.2023.2173333.

Abstract

Liposomes are versatile carriers that can encapsulate various drugs; however, for delivery to the brain, they must be modified with a targeting ligand or other modifications to provide blood-brain barrier (BBB) permeability, while avoiding rapid clearance by reticuloendothelial systems through polyethylene glycol (PEG) modification. BBB-penetrating peptides act as brain-targeting ligands. In this study, to achieve efficient brain delivery of liposomes, we screened the functionality of eight BBB-penetrating peptides reported previously, based on high-throughput quantitative evaluation methods with in vitro BBB permeability evaluation system using Transwell, in situ brain perfusion system, and others. For apolipoprotein E mimetic tandem dimer peptide (ApoEdp), which showed the best brain-targeting and BBB permeability in the comparative evaluation of eight peptides, its lipid conjugate with serine-glycine (SG)5 spacer (ApoEdp-SG-lipid) was newly synthesized and ApoEdp-modified PEGylated liposomes were prepared. ApoEdp-modified PEGylated liposomes were effectively associated with human brain capillary endothelial cells via the ApoEdp sequence and permeated the membrane in an in vitro BBB model. Moreover, ApoEdp-modified PEGylated liposomes accumulated in the brain 3.9-fold higher than PEGylated liposomes in mice. In addition, the ability of ApoEdp-modified PEGylated liposomes to localize beyond the BBB into the brain parenchyma in mice was demonstrated via three-dimensional imaging with tissue clearing. These results suggest that ApoEdp-SG-lipid modification is an effective approach for endowing PEGylated liposomes with the brain-targeting ability and BBB permeability.

Keywords: Apolipoprotein E mimetic peptide; blood–brain barrier; brain-targeting; liposomes; tissue clearing.

MeSH terms

  • Animals
  • Apolipoproteins / pharmacology
  • Apolipoproteins E
  • Brain
  • Drug Delivery Systems*
  • Endothelial Cells
  • Humans
  • Lipids / pharmacology
  • Liposomes* / pharmacology
  • Mice
  • Peptides / pharmacology
  • Polyethylene Glycols / pharmacology

Substances

  • Apolipoproteins
  • Lipids
  • Liposomes
  • Peptides
  • Polyethylene Glycols
  • Apolipoproteins E

Grants and funding

This study was partially supported by JSPS KAKENHI grant number 20H04540 (HA), Grant-in-Aid for JSPS Fellows JP20J21334 (NK), and Center for Clinical and Translational Research of Kyushu University Hospital (SK).